International Clinical Trial: A Phase 1, Open-Label, Randomized, Single-Dose Crossover Study to Evaluate the Potential Impact of High-fat Meal on the Pharmacokinetics of CRS3123 200 mg Capsule in Healthy Adult Participants

Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06988423) titled 'A Phase 1, Open-Label, Randomized, Single-Dose Crossover Study to Evaluate the Potential Impact of High-fat Meal on the Pharmacokinetics of CRS3123 200 mg Capsule in Healthy Adult Participants' on May 16.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Basic Science. Masking: None (Open Label).

Primary Sponsor: Crestone, Inc

Condition: Food Effect in Healthy Participants

Intervention: Drug: CRS3123 200 mg capsule

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: May 9, 2025

Target Sample Size: 18

Countr...